Grants
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) (PAR-25-226)
Sponsor
National Institute on Aging
Due Date
Multiple due dates; see announcement.